Introduction
Fracture risk is increased in people with type 2 diabetes (T2D) despite bone mass generally being normal or increased. [1] Clinical studies revealed decreased levels of circulating biochemical markers of bone formation and resorption in individuals with T2D [1] as well as lower bone formation and resorption and lower bone quality in bone biopsies in T2D. [2] The mechanisms behind these changes in bone turnover and the increased risk of fracture in T2D are not fully elucidated.
Inadequate secretion of insulin and insulin resistance are the cornerstones in the development of T2D. Insulin is considered bone anabolic due to stimulatory effects on osteoblast differentiation, [3] and mice not expressing the insulin receptor in osteoblasts have low bone mass. [4] Insulin signalling in osteoblasts favours osteoclast bone resorption activity through secretion of osteoprotegerin and, subsequently, generation and release of the undercarboxylated form of osteocalcin, an osteoblast-secreted marker of bone formation, which may stimulate insulin secretion from the pancreatic β-cells. [5] Furthermore, hyperglycaemia impairs osteoblast activity and survival [6] [7] [8] and promotes adipogenic rather than osteogenic differentiation of adipose and musclederived stem cells. [9] Additionally, gain-and-loss-of-function models of insulin signalling in mice osteoblasts provide evidence that a high fat diet causes insulin resistance in bone, which lowers bone turnover and osteocalcin activity, causing higher bone volume and glucose intolerance in mice. [10] Thus, based on preclinical investigations, insulin levels and beta-cell function as well as insulin sensitivity would be expected to correlate with markers of bone formation in humans, but clinical data from non-diabetic individuals remain to be established. Integration of bone and glucose homeostasis in humans is supported by direct associations between total osteocalcin and estimates of insulin secretion and sensitivity based on oral and intravenous glucose tolerance tests (OGTT or A C C E P T E D M A N U S C R I P T 4 IVGTT) [11] [12] [13] [14] and inverse associations with plasma glucose in T2D, [15] age-related increases in plasma glucose, [13] and incidence of T2D [16] [17] [18] . Also, markers of bone resorption but not bone formation were inversely associated with the incidence of T2D. [17] However, other investigations have not provided support of associations between total osteocalcin and plasma glucose or incident diabetes [19] [20] [21] [22] . Although the increased levels of fasting insulin usually observed in early stages of T2D could promote bone formation and subsequently bone resorption due to coupling of bone formation and resorption, possibly explaining the association between bone mineral density (BMD) and fasting insulin levels observed in some [23, 24] but not all epidemiological studies of nondiabetic individuals, [25] insulin resistance in bone cells may reduce bone formation and resorption, which are reported to be lower in patients with T2D. [1, 26] Corroborating these reports, insulin sensitivity assessed by an IVGTT was inversely associated with BMD in a selected group of nondiabetic, generally obese men with heart disease, [27] and homeostasis model assessment of insulin resistance (HOMA-IR) was positively associated with volumetric BMD in postmenopausal, nondiabetic women. [28] While these studies suggest that insulin resistance may increase bone mass, possibly due to lower bone turnover in T2D [26] , it remains unknown if insulin sensitivity measured using the gold standard, i.e. the hyperinsulinaemic, euglycaemic clamp and insulin secretion assessed by OGGT or IVGTT, are associated with bone turnover in non-diabetic individuals.
The aim of this study was to investigate the relationship between bone turnover using markers of bone resorption (CTX) and formation (P1NP), and insulin secretion and sensitivity assessed with the hyperinsulinaemic euglycaemic clamp and measures derived from intravenous and oral glucose tolerance tests in clinically healthy, non-diabetic men. Furthermore, we explored if bone turnover was associated with insulin secretion and 3-year changes in insulin secretion and sensitivity.
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Materials and methods
The mmol/l) were excluded. [29] In order to limit the effects of factors known or anticipated to influence bone and glucose homeostasis such as menstrual cycle, only male participants of the RISC study were selected for the present investigation.
Anthropometrics and lifestyle
Body height was measured using a standard ruler (stadiometer) without shoes. Waist size was measured on bare skin at the smallest point between costal edges and the iliac crest. Body weight and fat free mass (FFM) were measured with participants in light clothes and in the fasting state 
Biochemical tests
Blood samples were separated into serum and plasma and stored at -80 degrees until biochemical tests were performed. Samples were transferred on dry ice between sites and laboratories. Glucose was measured using the glucose oxidase technique (Cobas Integra, Roche) (within-and between assay coefficients of variation: 1.8% and 2.1%). Serum insulin and C-peptide were assessed using a two-sided time-resolved flouroimmunoassay (AutoDELFIA, Insulin Kit, Wallac Oy, Turku,
Finland) based on monoclonal antibodies (Within and between assay coefficients of variation:
Insulin (normal levels): 4.3% and 3.7%. C-peptide (normal levels): 5.3% and 2.6%). Serum
Procollagen type I amino-terminal propeptide (PINP) and C-telopeptide of type I collagen (CTX-1)
were measured by the chemiluminescence method in the fasting state and at steady-state of a euglycaemia during the clamp (IDS-iSYS. Within and between assay coefficients of variation (CV):
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7 PINP: 7% and 7%. CTX-1: 5% and 18%). Vitamin D was measured using direct competitive electrochemiluminescence immunoassay (COBAS 311, Roche).
Insulin sensitivity and beta-cell function
Based on the OGTT, participants were classified into two groups, individuals with normal glucose tolerance (NGT) or impaired glucose regulation (IGR), which included individuals with impaired fasting glycaemia (6.1-6.9 mmol/l), impaired glucose tolerance ( Beta-cell function was assessed as the total insulin secretion during the OGTT (ISR tot ) and beta-cell glucose sensitivity (GluSens), which reflects the response to changes in glucose levels. Furthermore, the ratio between the incremental insulin secretions assessed using C-peptide and plasma glucose concentration in the first 8 minutes after the intravenous glucose bolus were used to determine the acute insulin response (AIR) during IVGTT.
Statistics
Data are presented as percentages, and as mean (standard deviation) or median (interquartile range) as appropriate. First, the study population was stratified into two groups according to the glycaemic status, NGT or IGR. Second, differences in baseline anthropometrics as well as
measurements of fasting and insulin-stimulated levels of bone turnover markers and glucose homeostasis between individuals with NGT or IGR were investigated using Student's t-test, Mann-Whitney's test and Chi-square tests. Third, the associations between bone turnover markers and measures of insulin sensitivity and secretion were assessed using Lowess-plots and regression analyses. For the regression analyses, three different regression models were used: 1) adjusted for recruitment centre 2) further adjustment for age and BMI 3) further adjustment for smoking and physical activity (measured as a continuous variable) for the entire study population, and then for the normal glucose tolerance and the impaired glucose regulation groups. Skewed variables were log transformed prior to performing the regression analyses, which were performed with the available data and without imputations as data were assumed to be missing at random. These regression analyses were performed for the complete study population as no interaction between glycaemic statuses was observed. The regression models were repeated with adjustment for 25- 
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Results
Baseline anthropometrics and life style factors
Characteristics of the study population are presented in Table 1 . None of the participants were treated with corticosteroids or anti-resorptive drugs. Among the 576 non-diabetic men, 503 (87%) had NGT and 73 IGR. Age, body weight and BMI were higher in individuals with IGR (Table 1) .
Neither physical activity nor tobacco use differed between individuals with NGT and IGR ( Table 1) .
Glucose homeostasis
Insulin sensitivity assessed from the OGTT (OGIS-RISC) or from the hyperinsulinaemic euglycaemic clamp (M/I) was higher and HOMA-IR lower in individuals with NGT ( Table 2) .
Participants with NGT had lower ISR tot and higher GluSens during the OGTT than those with IGR (Table 2 ), while no difference in AIR during the IVGTT was observed between these groups.
The OGTT was repeated in 468 of the 576 (73%) participants after three years. Fasting plasma glucose (+0.2 mmol/L, p<0.001) and fasting serum insulin (+2 pmol/L, p<0.01) were slightly increased after 3-years follow-up. Moreover, ISR tot was increased (+2 pmol/L, p<0.001), insulin sensitivity assessed by OGIS-RISC was reduced (-0.3 μmol / min / Kg FFM , p<0.01), and HOMA-IR was increased (+0.6, p<0.001) after three years ( Table 2 ). Significant changes in these outcomes at follow-up were observed only in individuals with NGT, possibly due to lower number of individuals with IGR ( Table 2) .
Bone turnover markers
No differences in fasting levels of CTX and P1NP were observed between individuals with NGT and IGR (Table 1) . After 120 minutes of insulin stimulation (during the clamp), CTX and P1NP levels had decreased by 8.0% (p<0.001) and 1.9% (p<0.01), respectively ( Fig. 1 ). Decreases in both CTX and P1NP during insulin stimulation were observed in individuals with NGT, whereas only CTX decreased significantly in individuals with IGR (Table 1) . Vitamin D was measured in 77%
(n=451) of the participants. Vitamin D deficiency defined as a serum 25-OHD below 20 ng/dl was observed in 47% (n=211) of the study population, and the prevalence of vitamin D deficiency was comparable in individuals with NGT and IGR (Table 1) .
Relationship between bone turnover and glucose homeostasis
Both CTX and P1NP were inversely associated with fasting plasma glucose in the study population before and after adjustment for potential confounders, but these relations were not reflected in an association between bone turnover markers and fasting levels of serum insulin ( Table 3 ).
The relationships between bone turnover markers and measures of insulin sensitivity (OGIS-RISC
and Log-M/I) as well estimates of insulin secretion during IVGTT (AIR) and OGTT (ISR tot and GluSens) were first explored using Lowess plots (Supplementary material, a-f) but none of these plots pointed towards associations.
Nevertheless, insulin sensitivity determined by OGIS-RISC was directly associated with both bone turnover markers in the complete study population. However, the association disappeared after inclusion of age and BMI in the regression models ( Table 3 ). Neither of the bone turnover markers was associated with hyperinsulinaemic euglycaemic clamp-based measurements of insulin sensitivity (M/I) in unadjusted models. Insulin resistance assessed using the HOMA-IR was inversely associated with both CTX and P1NP in unadjusted analyses and remained inversely associated with P1NP but not CTX in the fully adjusted models. While insulin secretion during the IVGTT (AIR) was not associated with bone turnover markers either before or after adjustments, ISR tot during the OGTT was inversely associated with levels of P1NP in unadjusted but not adjusted models ( Table 3) .
As vitamin D deficiency could interfere with the assessment of a relationship between bone turnover markers and glucose homeostasis, regression analyses were repeated with adjustments for vitamin D levels (as a continuous variable) and in participants that were vitamin D replete (25-OHD
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11 ≥ 20 ng/dl), however, neither of the results of the regression analyses changed noticeably after these adjustments (data not shown).
Bone turnover markers and changes in insulin sensitivity and secretion
Baseline levels of neither P1NP nor CTX were associated with increases in fasting plasma glucose levels during follow-up (Table 4 ). Baseline levels of CTX and P1NP were not associated with changes in fasting serum insulin levels, ISR tot , OGIS-RISC, or HOMA-IR during follow-up (Table   4 ).
Discussion
The primary aim of this study was to investigate if bone turnover and insulin secretion and sensitivity are integrated in humans as expected, based on previous animal studies. We expected that levels of bone formation and resorption markers would be directly associated with insulin secretion, but neither of the bone turnover markers investigated were associated with insulin secretion capacity assessed using the IVGTT and the OGTT. Equally, we did not observe any relation between bone turnover markers and insulin sensitivity assessed using OGTT and the goldstandard method, i.e. hyperinsulinaemic euglycaemic clamp. Therefore, these results demonstrate that bone turnover assessed using bone turnover markers and peripheral insulin sensitivity and insulin secretion are unrelated in healthy, non-diabetic men.
Our observations are not in complete alignment with previous investigations. An inverse association between bone formation assessed using P1NP and insulin sensitivity determined using an IVGTT and a direct association between P1NP and insulin resistance based on HOMA-IR was observed in 63 men and women with NGT or IFG. [31] While we detected an inverse relation between P1NP and insulin sensitivity based on hyperinsulinaemic euglycaemic clamp in individuals with IGR, the association was only present after adjustments. These differences in observations may be explained by skeletal muscle or hepatic insulin resistance that leads to fasting hyperinsulinaemia, which promotes bone formation, or insulin resistance in bone, that impairs bone turnover. Furthermore, an inverse association between insulin resistance determined using HOMA-IR and bone resorption (CTX) but not formation (P1NP) was detected in 2955 elderly men, but neither of these bone turnover markers was associated with insulin resistance after adjustment for age, BMI and comorbidities. [17] Further, P1NP was directly associated with insulin resistance assessed on the basis of HOMA-IR in 1010 Swedish men aged 70-81 years prior to but not after adjustment for osteocalcin levels, suggesting that osteocalcin but not P1NP is independently associated with
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13 glucose homeostasis. [32] In addition, urinary NTX, a bone resorption marker, was not associated with fasting plasma glucose, whereas the level of osteocalcin was inversely associated with fasting plasma glucose in 380 elderly men. [13] Jointly, these previous investigations do not consistently support an association between BMTs such as P1NP and CTX and glucose homeostasis. In light of the results of the present investigation, which relies on measurements of insulin sensitivity assessed on the basis of both OGTT and hyperinsulinaemic euglycaemic clamp, evidence of an independent relationship between bone turnover markers and insulin sensitivity or indeed secretion is limited.
By contrast, levels of osteocalcin appear to represent more than just bone formation. Accordingly, undercarboxylated osteocalcin and total osteocalcin are inversely associated with fasting plasma glucose and insulin resistance and directly associated with insulin sensitivity in humans investigated using OGTT and hyperinsulinaemic euglycaemic clamp. [13, 15, [32] [33] [34] [35] These results emphasize that undercarboxylated osteocalcin and osteocalcin may reflect functions beyond that of bone remodelling. Furthermore, osteocalcin and undercarboxylated osteocalcin may predict changes in glucose levels or development of T2D according to some [13, 16, 17, 36] but not all prospective investigations. [20] [21] [22] Osteocalcin was not measured in the present investigation as osteocalcin is sensitivity to degradation, prompting blood samples for osteocalcin measurements to be chilled at 4
degrees Celsius immediately after being collected, which was not part of the protocol in our investigation. [37] Furthermore, assays that measure bioactive osteocalcin, i.e. osteocalcin decarboxylated specifically at residue Glu17, are unavailable in humans. [38] The potential integration of bone and glucose homeostasis in humans needs to be assessed using other biochemical markers that may not portray the physiological effects of alterations in levels of bioactive osteocalcin during bone remodelling. Rather than assessing osteocalcin, we investigated the ability of commonly used bone turnover markers to predict alterations in glucose homeostasis during a short follow-up period. In keeping with the cross-sectional data, bone turnover markers were not associated with changes in insulin sensitivity or insulin secretion after 3-years follow-up;
suggesting that bone turnover per se and glucose homeostasis are unrelated in healthy men.
The majority of previous clinical investigations have reported lower levels of bone turnover markers in individuals with type 1 or 2 diabetes than in controls. [26] Therefore, in order to investigate the relationship between bone turnover markers and glucose, insulin sensitivity and secretion independently of overt hyperglycaemia, patients with any type of diabetes were excluded from the present study. Although most of the study participants were glucose tolerant, a considerable number of participants had an abnormal glucose regulation. However, bone turnover markers were similar in those classified as either NGT or IGR suggesting that they may remain normal at least until development of overt hyperglycaemia. We observed decreases in the level of CTX and minor reductions in P1NP levels during a 2-hour hyperinsulinaemic euglycaemic clamp, which by design was similar to some of the studies that reported steady levels of bone turnover markers during insulin exposure. This disagreement may be explained by several factors including differences in the characteristics of the study population as the present investigation included substantially more individuals and was restricted to non-diabetic men, which may have reduced the variation, allowing us to identify alterations in bone turnover markers levels during insulin exposure. The overall effect of insulin on bone cell activity remains uncertain [42] . The decrease in P1NP and CTX during the clamp could be explained by several factors, including reduced levels of hormones known to promote bone activity such as IGF-1 or IGF-1 binding proteins, alterations in clearance of the bone turnover markers or inhibitory effects on osteoclasts activity, which leads to decreased osteoblast activity. CTX did not decrease in participants with IGR, but similar numerical changes in CTX levels were observed before and after insulin-stimulation, indicating that the discrepancy in CTX levels in the response to insulin stimulation between NGT and IGR could be explained by lower power. Importantly,
Investigation
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16 hyperinsulinaemic euglycaemic clamps relies on physiological insulin levels that are sustained beyond that observed in normal physiology; therefore, these changes in bone turnover markers may not represent the effects of physiological levels of insulin on bone turnover. Furthermore, the observed reductions in bone turnover markers are markedly smaller than those observed during consumption of food, [43] suggesting that the overall acute effect of intravenously administered insulin on bone turnover is minor.
Several factors need consideration when the results of the present investigation are to be interpreted.
We cannot exclude the possibility that the relationships between bone turnover markers and insulin secretion and sensitivity differ in individuals with manifest diabetes or in women. Furthermore, although adjustment for 25-OHD levels or restriction of the investigations to those that were vitamin D replete appeared not to change the results, it could be argued that the relationship between bone turnover markers and glucose homeostasis may vary between those with low and normal levels of vitamin D. Because BMD was not measured, we were unable to assess if the relationship between bone turnover markers and glucose homeostasis differed between individuals with high or low bone mass. Finally, although the size of the study population provided sufficient power to investigate the main aims, i.e. the relationships between bone turnover markers and insulin sensitivity and secretion, several comparisons without simultaneous adjustment for multiple testing were performed, which invariably increases the risk of spurious findings.
Conclusions
The present investigation showed that levels of commonly used biochemical markers of bone formation and resorption are not associated with insulin sensitivity and secretion assessed by use of different tests including hyperinsulinaemic euglycaemic clamp, IVGTT and OGTT in a very large study population of carefully characterized, non-diabetic men. Additionally, we did not observe any relationship between baseline bone turnover markers and 3-year changes in insulin sensitivity and Comparison of bone turnover markers at baseline and at 3-years: § p<0.05, § § p<0.01 and § § § p<0.001. 
ACCEPTED MANUSCRIPT
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28 Highlights -Markers of bone formation and resorption P1NP and CTX were inversely associated with fasting plasma glucose in non-diabetic men. -There were no association between the same biochemical markers of bone turnover and insulin sensitivity and secretion assessed using euglycaemic, hyperinsulinaemic clamps and intravenous glucose tolerance tests -Levels of CTX and P1NP decreased during the clamp (by 8% and 2%, respectively).
-Bone turnover markers do not predict changes in insulin sensitivity assessed using OGTT Figure 1 
